Biostar Pharmaceuticals, Inc. (BSPM)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
May 8, 2025, 4:00 PM EDT
Biostar Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | 2007 - 2011 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '17 Sep 30, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 | 2007 - 2011 |
| Revenue | 0.32 | 2.38 | 27.13 | 61.42 | 52.73 | 49.32 | Upgrade
|
| Revenue Growth (YoY) | -91.86% | -91.21% | -55.83% | 16.48% | 6.92% | -46.37% | Upgrade
|
| Cost of Revenue | 0.35 | 1.47 | 16.03 | 31.14 | 27.05 | 19.47 | Upgrade
|
| Gross Profit | -0.04 | 0.92 | 11.1 | 30.28 | 25.68 | 29.85 | Upgrade
|
| Selling, General & Admin | 4.12 | 3.6 | 13.29 | 26.21 | 22.67 | 33.84 | Upgrade
|
| Research & Development | 1.14 | 1.14 | 4.02 | 2.77 | 3.23 | 4.48 | Upgrade
|
| Operating Expenses | -2.82 | 4.48 | 21.98 | 28.97 | 24.93 | 41.99 | Upgrade
|
| Operating Income | 2.79 | -3.56 | -10.87 | 1.31 | 0.75 | -12.14 | Upgrade
|
| Interest Expense | -0.2 | -0.21 | -0.28 | -0.15 | -0.37 | -0.08 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0.01 | 1.33 | 1.34 | 0.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.5 | 0.22 | 0.24 | 0 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | 3.09 | -3.55 | -10.91 | 2.48 | 1.73 | -11.93 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 1.09 | 1.17 | - | Upgrade
|
| Asset Writedown | - | - | -2.97 | -2.62 | -0.24 | - | Upgrade
|
| Legal Settlements | 0.5 | 0.5 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -9.91 | 0.58 | - | -9.65 | Upgrade
|
| Pretax Income | 3.59 | -3.05 | -23.79 | 1.53 | 2.66 | -21.57 | Upgrade
|
| Income Tax Expense | 2.65 | 2.65 | 1.32 | -3.31 | 1.85 | -1.58 | Upgrade
|
| Net Income | 0.93 | -5.7 | -25.11 | 4.85 | 0.81 | -20 | Upgrade
|
| Net Income to Common | 0.93 | -5.7 | -25.11 | 4.85 | 0.81 | -20 | Upgrade
|
| Net Income Growth | - | - | - | 499.25% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 3 | 2 | 2 | 2 | 2 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 2 | 2 | 2 | 2 | 1 | Upgrade
|
| Shares Change (YoY) | 18.37% | 3.91% | 6.74% | 25.96% | 20.27% | 2.93% | Upgrade
|
| EPS (Basic) | 0.36 | -2.48 | -11.36 | 2.34 | 0.49 | -14.63 | Upgrade
|
| EPS (Diluted) | 0.34 | -2.50 | -11.40 | 2.30 | 0.49 | -14.63 | Upgrade
|
| EPS Growth | - | - | - | 369.39% | - | - | Upgrade
|
| Free Cash Flow | 8.59 | 4.91 | 5.82 | 0.44 | 7.93 | -3.62 | Upgrade
|
| Free Cash Flow Per Share | 3.28 | 2.14 | 2.63 | 0.21 | 4.82 | -2.65 | Upgrade
|
| Gross Margin | -11.56% | 38.38% | 40.93% | 49.30% | 48.71% | 60.53% | Upgrade
|
| Operating Margin | 876.46% | -149.48% | -40.07% | 2.13% | 1.42% | -24.62% | Upgrade
|
| Profit Margin | 294.01% | -238.98% | -92.56% | 7.89% | 1.53% | -40.55% | Upgrade
|
| Free Cash Flow Margin | 2702.11% | 206.03% | 21.44% | 0.72% | 15.03% | -7.33% | Upgrade
|
| EBITDA | 3.89 | -2.42 | -8.55 | 4.39 | 3.54 | -10.31 | Upgrade
|
| EBITDA Margin | 1225.43% | -101.56% | -31.52% | 7.15% | 6.70% | -20.91% | Upgrade
|
| D&A For EBITDA | 1.11 | 1.14 | 2.32 | 3.09 | 2.79 | 1.83 | Upgrade
|
| EBIT | 2.79 | -3.56 | -10.87 | 1.31 | 0.75 | -12.14 | Upgrade
|
| EBIT Margin | 876.46% | -149.48% | -40.07% | 2.13% | 1.42% | -24.62% | Upgrade
|
| Effective Tax Rate | 73.95% | - | - | - | 69.54% | - | Upgrade
|
| Advertising Expenses | - | - | 3.8 | 8.59 | 7.56 | 14.15 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.